CMB International: Maintains a "buy" rating on Collinpot Biopharmaceuticals-B (06990) with a target price raised to HKD 246.13.

CMB International expects to incur losses of 659 million yuan, 786 million yuan and 726 million yuan from 2024 to 2026.

Zhitong FinanceJun 11 04:09 ET

Columbotai Bio-B (06990.HK) nominated Lai Degui as a candidate for non-executive director

Gelonghui, May 31 | Columbotai Bio-B (06990.HK) announced that Dr. Wang Jingyi has resigned as the company's executive director with effect from May 31, 2024. The Board of Directors hereby announces that Mr. Lai Degui and Mr. Wan Peng have both resigned as supervisors of the Supervisory Board with effect from May 31, 2024. Following the resignation of Mr. Lai Degui mentioned above, Ms. Liao Yihong was elected Chairman of the Supervisory Board at the Supervisory Board meeting held on May 31, 2024. The board of directors has decided to nominate Mr. Lai Degui as a non-executive director candidate. It is proposed to appoint Mr. Lai Degui as a non-executive director and shareholder for the current year

Gelonghui FinanceMay 31 08:05 ET

Columbotai Bio-B (06990): Liao Yihong was elected Chairman of the Supervisory Board

According to Zhitong Finance App, Colunbotai Bio-B (06990) issued an announcement, effective May 31, 2024: Dr. Wang Jingyi has resigned as the company's executive director. Mr. Lai Degui and Mr. Wan Peng have both resigned as supervisors of the Supervisory Board. Ms. Liu Yihong was elected Chairman of the Supervisory Board at the Supervisory Board meeting held on May 31, 2024. Furthermore, the Board of Directors has decided to nominate Mr. Lai Degui as a non-executive director candidate. The proposal to appoint Mr. Lai Degui as a non-executive director is subject to shareholders' approval by means of an ordinary resolution at the recent Annual General Meeting of Shareholders.

Zhitong FinanceMay 31 08:04 ET

Express News | Sichuan Kelun-Biotech Biopharmaceutical - Wang Jingyi Resigned as an Executive Director

ReutersMay 31 08:02 ET

Changes in Hong Kong stocks | Collumbotai Bio-B (06990) is now up more than 5%. The company announced SKB264 clinical data and R&D capabilities in the ADC field will be recognized

Collumbotai Bio-B (06990) is now up more than 5%. As of press release, it has risen 4.54% to HK$165.7, with a turnover of HK$27.472,300.

Zhitong FinanceMay 29 22:04 ET

[Broker Focus] CITIC Construction Investment maintains Colun Botai Biotech (06990) “buy” rating, and it is expected that its R&D capabilities in the ADC field will be further recognized

Jinwu Financial News | According to the CITIC Construction Investment Research Report, Colunbotai Biotech (06990) published two clinical data on the core product SKB264 on ASCO. Among them, when used in combination with A167, it showed excellent efficacy in first-line treatment of advanced undriven gene mutation NSCLC, and was also safe; the single drug was also used as a phase III clinical result for TNBC terminal treatment. It is expected that this indication will be approved in the second half of the year. Partner MSD is actively deploying SKB264 global clinical trials. Currently, it has deployed 9 phase III clinical trials, covering various types of lung cancer, breast cancer, and endometrial cancer. Company purpose

金吾財訊May 29 03:48 ET